AstraZeneca announces USD 1.46 billion insitro deal: AstraZeneca stock trades at EUR 148.70

Published on 10/16/2026 at 09:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insitro gets USD 40 million upfront under the October 15, 2026 deal. AstraZeneca stock trades at EUR 148.70 on October 16, 2026 in Germany.

Collaboration and reporting dates

AstraZeneca announced the insitro collaboration on October 15, 2026, with USD 40 million upfront.
The agreement allows for up to USD 1.46 billion in development and commercial milestones.
AstraZeneca stock trades at EUR 148.70 at 9:41 a.m. CEST at Lang & Schwarz on October 16, 2026.
AstraZeneca plans to publish nine-month and third-quarter results on October 30, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und Impfstofffläschchen — AstraZeneca plc (ISIN GB0009895292) ist als forschendes Pharmaunternehmen an internationalen Börsen wie London gelistet, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) trades at EUR 148.70 at Lang & Schwarz on October 16, 2026 at 9:41 a.m. CEST as the company advances a USD 1.46 billion insitro collaboration announced on October 15, 2026. The deal includes USD 40 million upfront and up to USD 1.46 billion in development and commercial milestones, according to AstraZeneca.

AI targets two disease areas

The collaboration focuses on metabolic dysfunction-associated steatohepatitis, known as MASH, and cardiomyopathies. Insitro will use its Virtual Human platform to identify disease biology and advance AstraZeneca-nominated targets from discovery to development candidates.

AstraZeneca will hold exclusive worldwide rights to advance selected programs. It will also lead clinical development, regulatory work and commercialization, while insitro receives potential single-digit royalties on global sales.

What does the deal change?

The financial structure puts the immediate commitment at USD 40 million, while the potential milestone pool is 36.50 times larger at USD 1.46 billion. That difference makes the announcement a pipeline option rather than a near-term revenue event. Reuters reported on October 15, 2026, that AstraZeneca will run and fund future clinical trials as insitro applies machine learning and laboratory data to target discovery through Reuters.

Results date is October 30

AstraZeneca's investor-relations calendar lists an ESMO management event for October 26, 2026, followed by nine-month and third-quarter results on October 30, 2026. The company also lists a Rothschild roadshow for November 2, 2026, giving investors three dated milestones for the next reporting cycle, according to AstraZeneca.

Stock trades during Xetra hours

The euro quote places AstraZeneca stock at EUR 148.70 during the Xetra session on October 16, 2026. Citi had raised its London-listed target to GBp 18,600 from GBp 17,800 on October 6, 2026, while retaining a Buy rating, according to Proactive. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.